Zobrazeno 1 - 10
of 29
pro vyhledávání: ''
Autor:
Joseph L. Witztum, Yohan Bossé, Patrick Mathieu, Sotirios Tsimikas, Romain Capoulade, Jean-Pierre Després, Jean G. Dumesnil, Philippe Pibarot, James W. Tam, Xiaohong Yang, Koon K. Teo, Kwan L. Chan, Benoit J. Arsenault
Publikováno v:
Atherosclerosis. 260
Background and aims Elevated levels of lipoprotein(a) [Lp(a)] and oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) predict the progression of pre-existing mild-to-moderate calcific aortic valve stenosis (CAVS). Whether indirect markers of o
Publikováno v:
Atherosclerosis. 197:139-146
In a randomized, double-blind, crossover trial of 5-week treatment period with placebo or rosuvastatin (10 or 40 mg/day) with 2-week placebo wash-outs between treatments, the dose-dependent effect of rosuvastatin on apolipoprotein (apo) B-100 kinetic
Autor:
Seung Hwan Han, Kyung Cheon Lee, Jeong Yeal Ahn, Ichiro Sakuma, Hyung Sik Kim, Dong Kyu Jin, Eak Kyun Shin, Kwang Kon Koh
Publikováno v:
Atherosclerosis. 174:379-383
We investigated the effects of fenofibrate, peroxisome proliferator-activated receptors (PPARs) agonist, on endothelial function in patients with hypertriglyceridemia. We administered placebo or fenofibrate 200 mg daily to 25 patients with hypertrigl
Autor:
Benoît Lamarche, Mathieu Larivière, Claude Gagné, Jean Bergeron, Jean-Charles Hogue, Patrick Couture, Matteo Pirro
Publikováno v:
Atherosclerosis. 167:97-104
The effects of the HMG CoA reductase inhibitor atorvastatin on electrophoretic characteristics of LDL particles were evaluated in 46 patients (28 males and 18 females) with heterozygous familial hypercholesterolemia (FH) aged 20-61 carrying either a
Autor:
Reynald Dupuis, Pascal Egger, Arie van Tol, Maryse Guerin, Céline Soudant, M. John Chapman, Wilfried Le Goff
Publikováno v:
Atherosclerosis, 163, 287-296. Elsevier Ireland Ltd
Type IIB hyperlipidemia is associated with premature vascular disease, an atherogenic lipoprotein phenotype characterised by elevated levels of triglyceride-rich VLDL and small dense LDL, together with subnormal levels of HDL. The dose-dependent and
Autor:
Adam B. Polis, Baishali M. Ambegaonkar, Joanne E. Tomassini, Diane Tipping, Andrew M. Tershakovec
Publikováno v:
Atherosclerosis. 237(2)
Objective : Evaluate the lipid-altering effects of ezetimibe added to ongoing statin therapy, statin titration, switching from statin monotherapy to a more potent statin or to ezetimibe/simvastatin. Methods : A pooled analysis of patient-level data f
Publikováno v:
Atherosclerosis. 143:41-54
In a genetically heterogeneous group of 109 patients with a clinical diagnosis of heterozygous familial hypercholesterolaemia (FH), the influence of gender, apolipoprotein (apo) E genotype and the type of molecular defect in the LDL-receptor (LDLR) g
Autor:
Nicoline Hoogerbrugge, Hans Jansen
Publikováno v:
Atherosclerosis, 146, 167-174. Elsevier Ireland Ltd
The effects of atorvastatin (Lipitor) were evaluated in 40 patients with familial hypercholesterolemia (FH). Following a 6 week drug-free baseline period 20 male and 20 female patients were treated with atorvastatin 40 mg once daily (QD) for the init
Publikováno v:
Atherosclerosis. 128:11-18
Increased plasma cholesterol concentration in hypercholesterolemic patients is a major risk factor for atherosclerosis. The impaired removal of plasma low density lipoprotein (LDL) in these patients results in the presence of their LDL in the plasma
Autor:
Satoko Tamura, Masayoshi Shirakawa, Masashi Kikuchi, Hirotaka Numaguchi, Howard K. Surks, Mariko Nakagomi, Tamio Teramoto, Christine McCrary Sisk
Publikováno v:
Atherosclerosis. 230(1)
This study evaluated the effects of anacetrapib (ANA) on lipids and safety when administered as monotherapy or in combination with atorvastatin (ATV) in Japanese patients with dyslipidemia.Patients (n = 407) were randomized equally to 1 of 10 groups: